Tashatuvango / Shutterstock.com
Galderma Laboratories has successfully avoided three inter partes review (IPR) petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Foley & Lardner LLP, Dr. Reddy’s Laboratories, Oracea, Galderma Laboratories, inter partes review, IPR